vs

Side-by-side financial comparison of NEOGEN CORP (NEOG) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.

WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $224.7M, roughly 1.5× NEOGEN CORP). NEOGEN CORP runs the higher net margin — -7.1% vs -18.0%, a 10.9% gap on every dollar of revenue. On growth, NEOGEN CORP posted the faster year-over-year revenue change (-2.8% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $7.8M). Over the past eight quarters, NEOGEN CORP's revenue compounded faster (-0.9% CAGR vs -4.6%).

Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abuse...

Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.

NEOG vs WH — Head-to-Head

Bigger by revenue
WH
WH
1.5× larger
WH
$334.0M
$224.7M
NEOG
Growing faster (revenue YoY)
NEOG
NEOG
+73.4% gap
NEOG
-2.8%
-76.3%
WH
Higher net margin
NEOG
NEOG
10.9% more per $
NEOG
-7.1%
-18.0%
WH
More free cash flow
WH
WH
$160.2M more FCF
WH
$168.0M
$7.8M
NEOG
Faster 2-yr revenue CAGR
NEOG
NEOG
Annualised
NEOG
-0.9%
-4.6%
WH

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
NEOG
NEOG
WH
WH
Revenue
$224.7M
$334.0M
Net Profit
$-15.9M
$-60.0M
Gross Margin
47.5%
Operating Margin
-2.4%
Net Margin
-7.1%
-18.0%
Revenue YoY
-2.8%
-76.3%
Net Profit YoY
96.5%
-170.6%
EPS (diluted)
$-0.07
$-0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEOG
NEOG
WH
WH
Q1 26
$334.0M
Q4 25
$224.7M
$334.0M
Q3 25
$209.2M
$382.0M
Q2 25
$225.4M
$397.0M
Q1 25
$221.0M
$316.0M
Q4 24
$231.3M
$336.0M
Q3 24
$217.0M
$396.0M
Q2 24
$236.8M
$367.0M
Net Profit
NEOG
NEOG
WH
WH
Q1 26
$-60.0M
Q4 25
$-15.9M
$-60.0M
Q3 25
$36.3M
$105.0M
Q2 25
$-612.3M
$87.0M
Q1 25
$-10.9M
$61.0M
Q4 24
$-456.3M
$85.0M
Q3 24
$-12.6M
$102.0M
Q2 24
$-5.4M
$86.0M
Gross Margin
NEOG
NEOG
WH
WH
Q1 26
Q4 25
47.5%
Q3 25
45.4%
Q2 25
41.2%
Q1 25
49.9%
Q4 24
49.0%
Q3 24
48.4%
Q2 24
47.9%
Operating Margin
NEOG
NEOG
WH
WH
Q1 26
Q4 25
-2.4%
-11.4%
Q3 25
-7.7%
46.6%
Q2 25
-271.1%
37.8%
Q1 25
2.4%
35.4%
Q4 24
-197.8%
38.4%
Q3 24
1.0%
43.2%
Q2 24
5.5%
39.5%
Net Margin
NEOG
NEOG
WH
WH
Q1 26
-18.0%
Q4 25
-7.1%
-18.0%
Q3 25
17.4%
27.5%
Q2 25
-271.6%
21.9%
Q1 25
-4.9%
19.3%
Q4 24
-197.3%
25.3%
Q3 24
-5.8%
25.8%
Q2 24
-2.3%
23.4%
EPS (diluted)
NEOG
NEOG
WH
WH
Q1 26
$-0.80
Q4 25
$-0.07
$-0.77
Q3 25
$0.17
$1.36
Q2 25
$-2.82
$1.13
Q1 25
$-0.05
$0.78
Q4 24
$-2.10
$1.06
Q3 24
$-0.06
$1.29
Q2 24
$-0.02
$1.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEOG
NEOG
WH
WH
Cash + ST InvestmentsLiquidity on hand
$145.3M
$64.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1B
$468.0M
Total Assets
$3.4B
$4.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEOG
NEOG
WH
WH
Q1 26
$64.0M
Q4 25
$145.3M
$64.0M
Q3 25
$138.9M
$70.0M
Q2 25
$129.0M
$50.0M
Q1 25
$127.7M
$48.0M
Q4 24
$140.2M
$103.0M
Q3 24
$120.5M
$72.0M
Q2 24
$170.9M
$70.0M
Total Debt
NEOG
NEOG
WH
WH
Q1 26
Q4 25
$2.5B
Q3 25
$2.6B
Q2 25
$2.5B
Q1 25
$2.5B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
NEOG
NEOG
WH
WH
Q1 26
$468.0M
Q4 25
$2.1B
$468.0M
Q3 25
$2.1B
$583.0M
Q2 25
$2.1B
$570.0M
Q1 25
$2.7B
$579.0M
Q4 24
$2.7B
$650.0M
Q3 24
$3.1B
$583.0M
Q2 24
$3.1B
$623.0M
Total Assets
NEOG
NEOG
WH
WH
Q1 26
$4.2B
Q4 25
$3.4B
$4.2B
Q3 25
$3.4B
$4.3B
Q2 25
$3.4B
$4.3B
Q1 25
$4.0B
$4.2B
Q4 24
$4.1B
$4.2B
Q3 24
$4.5B
$4.2B
Q2 24
$4.5B
$4.2B
Debt / Equity
NEOG
NEOG
WH
WH
Q1 26
Q4 25
5.37×
Q3 25
4.43×
Q2 25
4.44×
Q1 25
4.29×
Q4 24
3.72×
Q3 24
4.19×
Q2 24
3.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEOG
NEOG
WH
WH
Operating Cash FlowLast quarter
$19.4M
$367.0M
Free Cash FlowOCF − Capex
$7.8M
$168.0M
FCF MarginFCF / Revenue
3.5%
50.3%
Capex IntensityCapex / Revenue
5.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.5M
$437.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEOG
NEOG
WH
WH
Q1 26
$367.0M
Q4 25
$19.4M
$152.0M
Q3 25
$10.9M
$86.0M
Q2 25
$16.4M
$70.0M
Q1 25
$19.5M
$59.0M
Q4 24
$40.3M
$134.0M
Q3 24
$-17.9M
$79.0M
Q2 24
$26.7M
$1.0M
Free Cash Flow
NEOG
NEOG
WH
WH
Q1 26
$168.0M
Q4 25
$7.8M
$136.0M
Q3 25
$-13.1M
$75.0M
Q2 25
$349.0K
$58.0M
Q1 25
$-13.4M
$52.0M
Q4 24
$23.1M
$109.0M
Q3 24
$-56.3M
$71.0M
Q2 24
$2.5M
$-6.0M
FCF Margin
NEOG
NEOG
WH
WH
Q1 26
50.3%
Q4 25
3.5%
40.7%
Q3 25
-6.3%
19.6%
Q2 25
0.2%
14.6%
Q1 25
-6.1%
16.5%
Q4 24
10.0%
32.4%
Q3 24
-26.0%
17.9%
Q2 24
1.1%
-1.6%
Capex Intensity
NEOG
NEOG
WH
WH
Q1 26
Q4 25
5.2%
4.8%
Q3 25
11.5%
2.9%
Q2 25
7.1%
3.0%
Q1 25
14.9%
2.2%
Q4 24
7.4%
7.4%
Q3 24
17.7%
2.0%
Q2 24
10.2%
1.9%
Cash Conversion
NEOG
NEOG
WH
WH
Q1 26
Q4 25
Q3 25
0.30×
0.82×
Q2 25
0.80×
Q1 25
0.97×
Q4 24
1.58×
Q3 24
0.77×
Q2 24
0.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEOG
NEOG

Other$109.2M49%
Bacterial And General Sanitation$44.9M20%
Services$25.7M11%
Natural Toxins And Allergens$20.4M9%
Animal Care$8.9M4%
Genomics Services$6.3M3%
Biosecurity Products$4.6M2%
Life Sciences$1.4M1%

WH
WH

Fee-related and other revenues$334.0M100%
Management and other fees$2.0M1%

Related Comparisons